Renhuang Pharmaceuticals, Inc. RHGP has bought prime time advertising slots in Central Chinese Television’s (CCTV) 2008 “Gold Ad” auction, following two of the national television network’s most heavily watched programs.
Watch this — major advertising as you well know — particularly pharmaceutical advertising coupled with the evening news has been incredibly successful in the United States.
But wait, there’s a twist. Remember how many people tuned in to watch Katie Couric? Well, it may be deja vu all over again in China’s evening news. RHBP bought time in 7.5 second and 15 second air times follow CCTV’s evening news and the newsmagazine show, “Topics in Focus.”, both of which are top-rated television programs in China.
This could NOT have come at a better time. China is riveted by CCTV’s prime-time 7pm news being read by a FEMALE!
Female anchors are new for China and BIG.
CCTV news programming director Liang Xiaotao refused to say whether Hai Xia would be a regular fixture on the anchor desk.
This comes on the heels of RHGP’s fiscal year-to-date results covering the nine months from October 1, 2006 to July 31, 2007, indicating net earnings of $8.46 million on solid sales of about $21 million, more than doubling the net earnings of $3.08 million for the Company’s operating subsidiary for the same period of the previous year.
RHGP controls an estimated 70% of China’s natural resources of Acanthopanax (also known as Siberian Ginseng), the Company possesses a unique competitive edge and occupies a dominant market position in Acanthopanax-based medicinal and nutraceutical products.
This is crucial advertising with the potential to move sales.
Source:
Pub Med and
Renhuang Pharmaceuticals, Inc.
No. 281, Taiping Road, Taiping District
Harbin, Heilongjiang Province, 150050
P. R. China
About Renhuang Pharmaceuticals, Inc.: Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang’s key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China’s natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. The Company has achieved a significant progress in research & development of standard extraction, separation of effective components, and medication with specificity. Several of these products have already been submitted for approval by the State Food and Drug Administration (”SFDA”). These products are expected to have a substantial upside growth potential due to their insufficient supply in China. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes.
Safe Harbor Statement: This press release contains certain statements that may include ‘forward-looking statements’ as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are ‘forward-looking statements.’ Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Disclosure: Pentony Enterprises LLC has been compensated $12,300.00 for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.
